Lian‐Yu Lin

The paper evaluates the clinical impact of pharmacogenetic risk variants in a large Han Chinese cohort, finding that while most carry risk variants, the excess risk of adverse events is small and most patients do not experience adverse outcomes.

This study identifies drug-like inhibitors that block TSG101-UEV/PTAP interactions, impairing viral budding and replication across multiple virus families.

The paper compares the pathogenicity-related gene repertoires between Pyricularia oryzae and Pyricularia penniseti, revealing significant genomic differences.